AstraZeneca PLC

NASDAQ:AZNUnited States

AstraZeneca PLC is a science-led biopharmaceutical company. It discovers, develops, and commercializes prescription medicines in oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal and metabolism, respiratory and immunology and vaccines and immune therapies. Its key marketed oncology products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Zoladex, Faslodex and others. Its rare diseases products include Soliris, Ultomiris, Strensiq and Kanuma. Its biopharmaceuticals products include Farxiga, Crestor, Breztri and others. Its investigational vaccine candidate IVX-A12, which targets both respiratory syncytial virus and human metapneumovirus. Its oncology candidate includes FPI-2265 targeting prostate specific membrane antigen for metastatic castration resistant prostate cancer, which is in a Phase II trial. It also discovers, develops, and manufactures T-cell receptor therapies. Its Eneboparatide is an investigational therapeutic peptide.

Contact Information

Headquarters

1 Francis Crick Avenue Cambridge Biomedical CampusCAMBRIDGE, United Kingdom CB2 0AA

Phone

207-304-5000

Fax

207-604-8151

Executives

Non-Executive Independent Chairman of the Board

Michel Demare

Chief Executive Officer, Executive Director

Pascal Soriot

Chief Financial Officer, Executive Director

Aradhana Sarin

Chief Executive Officer - Alexion, Chief Strategy Officer - AstraZeneca

Marc Dunoyer

Chief Human Resource Officer, Chief Compliance Officer, General Counsel

Jeffrey Pott